Online inquiry

IVTScrip™ mRNA-Human ANXA2R, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WK20360MR)

This product GTTS-WK20360MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the ANXA2R protein. This product can be used in Natural killer T (NKT) cell-related researches.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001014279.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 389289
UniProt ID Q3ZCQ2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ANXA2R, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WK20360MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK17955MR IVTScrip™ mRNA-Human ANTXR1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ANTXR1
GTTS-WK22325MR IVTScrip™ mRNA-Human ARID4A, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARID4A
GTTS-WK19716MR IVTScrip™ mRNA-Human ANKRD30BP2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ANKRD30BP2
GTTS-WK8644MR IVTScrip™ mRNA-Human ADGRG6, (Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ADGRG6
GTTS-WK25637MR IVTScrip™ mRNA-Human ARL16, (Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARL16
GTTS-WK12508MR IVTScrip™ mRNA-Human ADAMTSL1, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADAMTSL1
GTTS-WK25941MR IVTScrip™ mRNA-Human ARL4A, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARL4A
GTTS-WK25298MR IVTScrip™ mRNA-Human ARHGAP39, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP39
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW